CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
Walls GM., Oughton JB., Chalmers AJ., Brown S., Collinson F., Forster MD., Franks KN., Gilbert A., Hanna GG., Hannaway N., Harrow S., Haswell T., Hiley CT., Hinsley S., Krebs M., Murden G., Phillip R., Ryan AJ., Salem A., Sebag-Montefoire D., Shaw P., Twelves CJ., Walker K., Young RJ., Faivre-Finn C., Greystoke A.
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.